跳转至内容
Merck
CN

Y0000881

布洛芬

European Pharmacopoeia (EP) Reference Standard

别名:

α-甲基-4-(异丁基)苯乙酸, (±)-2-(4-异丁基苯基)丙酸

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C13H18O2
CAS号:
分子量:
206.28
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

ibuprofen

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

格式

neat

储存温度

−20°C

SMILES字符串

CC(C)Cc1ccc(cc1)C(C)C(O)=O

InChI

1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)

InChI key

HEFNNWSXXWATRW-UHFFFAOYSA-N

基因信息

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets, has been developed and issued under the Authority of the Issuing Pharmacopoeia.

For further information and support please go to the website of the issuing Pharmacopoeia.

应用

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia. Their suitability for any other use is not guaranteed and is the sole responsibility of the user. This standard is not intended for human or animal use.
Established for the preparation of reference solution (c) in testing for related substances and impurities in ibuprofen using liquid chromatography (General text 2.2.29), according to the monograph 0721 of European Pharmacopeia.

生化/生理作用

环加氧酶 (COX) 抑制剂,对 COX-1 的抑制活性大于对 COX-2 的抑制活性。

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

相关产品

产品编号
说明
价格

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Oral - Eye Irrit. 2 - STOT SE 3

靶器官

Respiratory system

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Ibuprofen
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 2921-2923 (2017)
R O Day et al.
Clinical pharmacology and therapeutics, 43(5), 480-487 (1988-05-01)
The simultaneous disposition of the enantiomers of ibuprofen in synovial fluid and plasma was studied in eight patients with arthritis. Concentrations of the active S-enantiomer in synovial fluid exceeded those of the R-enantiomer at all times in all patients with
Sheena Derry et al.
The Cochrane database of systematic reviews, 10(10), CD007550-CD007550 (2013-10-24)
This review is an update of a previously published review in The Cochrane Database of Systematic Reviews Issue 3, 2009 on single dose oral dexibuprofen (S(+)-ibuprofen) for acute postoperative pain in adults.Dexibuprofen is a non-steroidal anti-inflammatory drug (NSAID) licensed for
J B Whitlam et al.
Clinical pharmacology and therapeutics, 29(4), 487-492 (1981-04-01)
Free and total ibuprofen levels in serum and synovial fluid (SF) were determined in one male and 14 female arthritic patients (mean age 56 yr, range 19 to 77) after 400 mg three times daily for 2 days. Free drug
Bart Van Overmeire et al.
Lancet (London, England), 364(9449), 1945-1949 (2004-11-30)
Ibuprofen is used for treatment and prevention of patent ductus arteriosus in low-birthweight infants. Its effects on regional circulations differ from those of indometacin. Because prophylactic indometacin reduces the frequency of severe intraventricular haemorrhage and patent ductus arteriosus, we aimed

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门